

FIG. 1A




x10 magnification




x20 magnification

FIG. 1B



x5 magnification



x5 magnification

FIG. 2



[File 32231s2]
Arbitrary y scale
1
0.75
0.5
0.25
5
10
15
20
25
30
35
40
θ-2θ (deg)

FIG. 3



Arbitrary y scale
1
0.75
0.5
0.25
5
10
15
20
25
30
35
40
θ-2θ (deg)
[File: 131232] 79088, 2120-57, SEP-225289-01

FIG. 4




FIG. 5



[File: 80120]
Arbitrary y scale
1
0.75
0.5
0.25
5
10
15
20
25
30
35
40
θ-2θ (deg)

FIG. 6



Arbitrary y scale
1
0.75
0.5
0.25
5
10
15
20
25
30
35
40
θ-2θ (deg)
[File: 139334] 80120, 2164-69, SEP-225289-01

FIG. 7



C6
N41
C4
C7
C3
Cl13
C5
C12
C8
C10
C2
C13
C9
C14
Cl14
Cl
C1
C11
C15
C16
O1w

FIG. 8




AU
Minutes
Degradant II
17.441
Transnorsertraline HCl - 20.038
(1R,4S)-Acetamide - 29.592
Tetralone - 30.973

FIG. 9


1 mg capsule, 40 C/75% RH,
8 w, dev. stab. study
API and A-TAB
AU
Minutes
0.080
0.070
0.060
0.050
0.040
0.030
0.020
0.010
0.000
-0.010
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00